NCT06390865 2025-11-04
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT06385496 2025-10-31
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02484430 2025-03-03
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT02727777 2020-03-12
Phase II Study of TAK228 in Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03205891 2018-01-17
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01118689 2013-08-02
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc.
Phase 1 Completed